Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Trans-Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. It was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 54.00 | |
10 mg | In stock | $ 87.00 | |
25 mg | In stock | $ 148.00 | |
50 mg | In stock | $ 237.00 | |
100 mg | In stock | $ 353.00 | |
200 mg | In stock | $ 523.00 | |
500 mg | In stock | $ 837.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 58.00 |
Description | Trans-Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. It was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis. |
In vivo | Protodioscin (5 and 10 mg/kg) significantly improves glucose intolerance and reduced the levels of serum UA, BUN, Cr, TC and TG. Protodioscin significantly reduces renal concentrations of IL-1β, IL-6 and TNF-α by inhibiting the activation of nuclear factor-κB, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase and extracellular signal-regulated kinase[1]. Protodioscin ameliorates the death rate, inhibits the increase in neurological deficit scores and infarct volume, and reduces the apoptotic nerve cells induced by MCAO in rats. Protodioscin attenuates the change of relevant apoptins, suppresses the release of pro-inflammatory cytokines in serum and reverses the protein expression of NF-κB (in nucleus and cytoplasm) and IκBα (in cytoplasm) induced by MCAO in rats[2]. Protodioscin (0.5?mg/kg, i.p.) increases the coagulation time by appr?50?% as compared to that of high-fat diet control rats. Protodioscin possesses a promising effect in lowering the blood levels of both lipoproteins, especially LDL, thus resulting in a high ratio of HDL/LDL[3]. |
Synonyms | Tranilast trans- |
Molecular Weight | 327.33 |
Formula | C18H17NO5 |
CAS No. | 70806-55-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL(183.3 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Trans-Tranilast 70806-55-2 Endocrinology/Hormones RAAS Trans Tranilast trans-SB 252218 Inhibitor Angiotensin Receptor TransTranilast Tranilast trans- trans-Tranilast inhibit inhibitor